본문 바로가기
KERD
논문KCI 등재

Effects of the Antioxidant Sulforaphane on Hyperlocomotion and Prepulse Inhibition Deficits in Mice after Phencyclidine Administration

갠지하시모토|Yuko Fujita|Yumi Shirai
대한정신약물학회 (Korean College of Neuropsychopharmacology)|2012.08|Clinical Psychopharmacology and Neuroscience|제10권 제2호|pp. 94-98|DOI http://dx.doi.org/

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

SchizophreniaAntioxidantsSulforaphanePhencyclidinePrepulse inhibitionNrf2 activator

초록

Objective: Accumulating evidence suggests that oxidative stress plays a role in the pathophysiology of schizophrenia and that the potent antioxidants may be potential therapeutic drugs for schizophrenia. This study was undertaken to examine the effects of the potent antioxidant sulforaphane (SFN), found in cruciferous vegetables, on behavioral abnormalities (e.g., hyperlocomotion and prepulse inhibition [PPI] deficits) in mice after a single administration of the N-methyl-D-aspartate (NMDA)-receptor antagonist phencyclidine (PCP). Methods: Effects of SFN (3, 10, and 30 mg/kg, intraperitoneally [i.p.]) on hyperlocomotion and PPI deficits in the adult male ddY mice after administration of PCP (3.0 mg/kg, subcutaneously [s.c.]) were examined. Results:Administration of SFN (30 mg/kg, intraperitoneally [i.p.]), but not low doses (3 and 10 mg/kg, i.p.), significantly attenuated hyperlocomotion in mice after PCP administration (3.0 mg/kg, subcutaneously [s.c.]). Furthermore, administration of SFN (3, 10, and 30 mg/kg, i.p.) attenuated the PPI deficits in mice after PCP administration (3.0 mg/kg, s.c.) in a dose-dependent manner. Conclusion: These results suggest that SFN has antipsychotic activity in an animal model of schizophrenia. Therefore, it is likely that SFN may be a potential therapeutic drug for schizophrenia.

Abstract

Objective: Accumulating evidence suggests that oxidative stress plays a role in the pathophysiology of schizophrenia and that the potent antioxidants may be potential therapeutic drugs for schizophrenia. This study was undertaken to examine the effects of the potent antioxidant sulforaphane (SFN), found in cruciferous vegetables, on behavioral abnormalities (e.g., hyperlocomotion and prepulse inhibition [PPI] deficits) in mice after a single administration of the N-methyl-D-aspartate (NMDA)-receptor antagonist phencyclidine (PCP). Methods: Effects of SFN (3, 10, and 30 mg/kg, intraperitoneally [i.p.]) on hyperlocomotion and PPI deficits in the adult male ddY mice after administration of PCP (3.0 mg/kg, subcutaneously [s.c.]) were examined. Results:Administration of SFN (30 mg/kg, intraperitoneally [i.p.]), but not low doses (3 and 10 mg/kg, i.p.), significantly attenuated hyperlocomotion in mice after PCP administration (3.0 mg/kg, subcutaneously [s.c.]). Furthermore, administration of SFN (3, 10, and 30 mg/kg, i.p.) attenuated the PPI deficits in mice after PCP administration (3.0 mg/kg, s.c.) in a dose-dependent manner. Conclusion: These results suggest that SFN has antipsychotic activity in an animal model of schizophrenia. Therefore, it is likely that SFN may be a potential therapeutic drug for schizophrenia.

참고문헌 (54)

  1. Javitt DC, "Recent advances in the phencyclidine model of schizophrenia", Am J Psychiatry, 148, pp.1301~1308 (1991)
  2. Olney JW, "Glutamate receptor dysfunction and schizophrenia", Arch Gen Psychiatry, 52, pp.998~1007 (1995)
  3. Coyle JT, "The glutamatergic dysfunction hypothesis for schizophrenia", Harv Rev Psychiatry, 3, pp.241~253 (1996)
  4. Krystal JH, "NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders", Harv Rev Psychiatry, 7, pp.125~143 (1999)
  5. Hashimoto K, "Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia", Arch Gen Psychiatry, 60, pp.572~576 (2003)
  6. Gaisler-Salomon I, "How high-resolution basal-state functional imaging can guide the development of new pharmacotherapies for schizophrenia", Schizophr Bull, 35, pp.1037~1044 (2009)
  7. Hashimoto K, "Dysfunction of glia-neuron communication in pathophysiology of schizophrenia", Curr Psychiatry Rev, 1, pp.151~163 (2005)
  8. Kenji Hashimoto, "The NMDA Receptor Hypofunction Hypothesis for Schizophrenia and Glycine Modulatory Sites on the NMDA Receptors as Potential Therapeutic Drugs", Clinical Psychopharmacology and Neuroscience, 4(1), pp.3~10 (2006), 대한정신약물학회
  9. Krystal JH, "Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses", Arch Gen Psychiatry, 51, pp.199~214 (1994)
  10. Anand A, "Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists", Arch Gen Psychiatry, 57, pp.270~276 (2000)
  11. Krystal JH, "Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia", Arch Gen Psychiatry, 59, pp.663~664 (2002)
  12. Krystal JH, "Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function", Arch Gen Psychiatry, 62, pp.985~994 (2005)
  13. Jentsch JD, "The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia", Neuropsychopharmacology, 20, pp.201~225 (1999)
  14. Hashimoto K, "Phencyclidineinduced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol", Eur J Pharmacol, 519, pp.114~117 (2005)
  15. Hashimoto K, "Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of alpha7 nicotinic receptors", Eur J Pharmacol, 553, pp.191~195 (2006)
  16. Hashimoto K, "Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors", Neuropsychopharmacology, 32, pp.514~521 (2007)
  17. Hashimoto K, "Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711", Biol Psychiatry, 63, pp.92~97 (2008)
  18. Hashimoto K, "Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine", Eur Neuropsychopharmacol, 18, pp.414~421 (2008)
  19. Hagiwara H, "Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors", Eur Neuropsychopharmacol, 18, pp.448~454 (2008)
  20. Tanibuchi Y, "Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: a possible role of alpha1-adrenoceptors", Eur Neuropsychopharmacol, 19, pp.861~867 (2009)
  21. Braff DL, "Sensorimotor gating and schizophrenia. Human and animal model studies", Arch Gen Psychiatry, 47, pp.181~188 (1990)
  22. Swerdlow NR, "Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients", Arch Gen Psychiatry, 51, pp.139~154 (1994)
  23. Perry W, "Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients", Arch Gen Psychiatry, 56, pp.277~281 (1999)
  24. Geyer MA, "Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review", Psychopharmacology, 156, pp.117~154 (2001)
  25. Bakshi VP, "Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response", J Pharmacol Exp Ther, 271, pp.787~794 (1994)
  26. Javitt DC, "Effects of phencyclidine on prepulse inhibition of acoustic startle response in the macaque", Psychopharmacology, 156, pp.165~168 (2001)
  27. Yee BK, "The Effects of dizocilpine and phencyclidine on prepulse inhibition of the acoustic startle reflex and on prepulse-elicited reactivity in C57BL6 mice", Neuropsychopharmacology, 29, pp.1865~1877 (2004)
  28. Egerton A, "Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats", Psychopharmacology, 198, pp.37~49 (2008)
  29. Mahadik SP, "Free radical pathology and antioxidant defense in schizophrenia: a review", Schizophr Res, 19, pp.1~17 (1996)
  30. Matsuzawa D, "Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study", PLoS One, 3, pp.e1944~ (2008)
  31. Hashimoto K, "Regarding "N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial"", Biol Psychiatry, 64, pp.e1~ (2008)
  32. Do KQ, "Redox dysregulation and oxidative stress in schizophrenia: nutrigenetics as a challenge in psychiatric disease prevention", World Rev Nutr Diet, 101, pp.131~153 (2010)
  33. Yao JK, "Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view", Antioxid Redox Signal, 15, pp.2011~2035 (2011)
  34. Chowdari KV, "Genetic association studies of antioxidant pathway genes and schizophrenia", Antioxid Redox Signal, 15, pp.2037~2045 (2011)
  35. Reddy R, "Antioxidant therapeutics for schizophrenia", Antioxid Redox Signal, 15, pp.2047~2055 (2011)
  36. Matsuzawa D, "Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia", Antioxid Redox Signal, 15, pp.2057~2065 (2011)
  37. Martins-de-Souza D, "The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics", Antioxid Redox Signal, 15, pp.2067~2079 (2011)
  38. Bitanihirwe BK, "Oxidative stress in schizophrenia: an integrated approach", Neurosci Biobehav Rev, 35, pp.878~893 (2011)
  39. Zhang Y, "Cancer-preventive isothiocyanates: dichotomous modulators of oxidative stress", Free Radic Biol Med, 38, pp.70~77 (2005)
  40. Juge N, "Molecular basis for chemoprevention by sulforaphane: a comprehensive review", Cell Mol Life Sci, 64, pp.1105~1127 (2007)
  41. Yanaka A., "Sulforaphane enhances protection and repair of gastric mucosa against oxidative stress in vitro, and demonstrates anti-inflammatory effects on Helicobacter pyloriinfected gastric mucosae in mice and human subjects", Curr Pharm Des, 17, pp.1532~1540 (2011)
  42. Cheung KL, "Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention", AAPS J, 12, pp.87~97 (2010)
  43. Kwak MK, "Targeting NRF2 signaling for cancer chemoprevention", Toxicol Appl Pharmacol, 244, pp.66~76 (2010)
  44. Chen H, "Protective effects of the antioxidant sulforaphane on behavioral changes and neurotoxicity in mice after the administration of methamphetamine", Psychopharmacology, 222, pp.37~45 (2012)
  45. Zhang L, "Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine", Neuropsychopharmacology, 32, pp.2004~2010 (2007)
  46. Hashimoto K, "Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine", Biol Psychiatry, 65, pp.1103~1106 (2009)
  47. Horio M, "Effects of D-amino acid oxidase inhibitor on the extracellular D-alanine levels and the efficacy of D-alanine on dizocilpine-induced prepulse inhibition deficits in mice", Open Clin Chem J, 2, pp.16~21 (2009)
  48. Takatsu Y, "Orally active glutamate carboxypeptidase II inhibitor 2-MPPA attenuates dizocilpine-induced prepulse inhibition deficits in mice", Brain Res, 1371, pp.82~86 (2011)
  49. Jazwa A, "Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism", Antioxid Redox Signal, 14, pp.2347~2360 (2011)
  50. Hashimoto K, "Glycine transporter-1: a new potential therapeutic target for schizophrenia", Curr Pharm Des, 17, pp.112~120 (2011)
  51. Ishikawa M, "α7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia", Curr Pharm Des, 17, pp.121~129 (2011)
  52. Niitsu T, "Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases", Curr Pharm Des, 18, pp.875~883 (2012)
  53. Yoshida T, "Recent advances in the potential therapeutic drugs for cognitive deficits in schizophrenia", Curr Psychiatry Rev, 8, pp.140~150 (2012)
  54. Yanaka A, "Dietary sulforaphane-rich broccoli sprouts reduce colonization and attenuate gastritis in Helicobacter pylori-infected mice and humans", Cancer Prev Res, 2, pp.353~360 (2009)

관련 논문AI추천

An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia갠지하시모토, Akihiro Shiina, Masaomi Iyo, Nobuhisa Kanahara, Tadashi Hasegawa, Taisuke Yoshida, Tasuku Hashimoto, Tsuyoshi Sasaki, Yasunori Oda대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2015 · 제13권 제1호Effects of Cilostazol on Dizocilpine-induced Hyperlocomotion and Prepulse Inhibition Deficits in Mice갠지하시모토, Hiroko Hagiwara, Mao Horio, Masaomi Iyo, Yuko Fujita, Yuko Tanibuchi대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2010 · 제8권 제2호Effects of Quetiapine on Dizocilpine-induced Prepulse Inhibition Deficits in Mice: Possible Role of the aα1 Adrenergic Receptor갠지하시모토, Mao Horio, Masaomi Iyo, Yuko Fujita, Yuko Tanibuchi대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2010 · 제8권 제3호Effects of Cilostazol on Cognitive Deficits in Mice after Repeated Administration of Phencyclidine갠지하시모토, Hiroko Hagiwara, Mao Horio, Masaomi Iyo, Tamaki Ishima, Yuko Fujita, Yuko Tanibuchi대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2010 · 제8권 제1호Differential Effects of Olanzapine and Haloperidol on MK-801-induced Memory Impairment in Mice김영훈, 박성우, 서미경, 송재천, 이정구대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2016 · 제14권 제3호Electroencephalographic Power Spectral Profile in a Rat Model of Schizophrenia이만기, Hwan Soo Jang, Hyeon Ryeol Jo, Hyo Soon Choi, Jae Hyun Lim, Jong Ho Kim대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2009 · 제7권 제1호

이 간행물의 다른 논문 (8건)

A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in SchizophreniaJimmy Lee, Siow-Ann Chong, Milawaty Nurjonopp. 61-70Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical ReviewGavin P. Reynoldspp. 71-77Treatment Response in First-episode SchizophreniaHans-Jürgen Möller, Rebecca Schennachpp. 78-87Assessment between Dopamine Receptor D2 (DRD2) Polymorphisms and Schizophrenia in Korean Population이상민, 김수강, 조아랑, 정주호, 강원섭pp. 88-93Use of Clozapine for the Treatment of Schizophrenia: Findings of the 2006 Research on the China Psychotropic Prescription StudiesJian-Guo Shi, Xin Yu, Hong Ma, Tian-Mei Si, Yun-shu Zhang, Liang Shu, Ke-Qing Li, Xie-He Liu, Qi-Yi Mei, Gao-Hua Wang, Pei-Shen Bai, Li-Ping Ji, Xian-Sheng Cheng, Cui Ma, Hong-Yan Zhangpp. 99-104
원문 보기